Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000, Australia

hello@breathelifesciences.com

+61 2 9078 8180

16 November 2026

BLS Pharmaceuticals to Present at Bell Potter Healthcare Conference

BLS Pharmaceuticals Limited (ASX: BLS) ("BLS" or "the Company") is pleased to advise that CEO Sam Watson and Executive Director and COO Jason Hine will present at the virtual Bell Potter Healthcare Conference on Thursday 19 November 2026 at 4:30pm AEDT.

The presentation will provide an overview of BLS's pharmaceutical manufacturing operations, financial performance and international expansion, including its growing presence in Germany and the United Kingdom.

The Bell Potter Healthcare Conference will be held virtually from 17-19 November 2026.

The presentation will be available to eligible Bell Potter clients via the Bell Potter Client Access platform.

Approved by the Board of BLS Pharmaceuticals Limited for release to the ASX.

For further information, please contact:

BLS Pharmaceuticals Limited

Sam Watson
Chief Executive Officer
hello@blspharma.com

NWR Communications

Melissa Tempra
Media & Investor Relations
melissa@nwrcommunications.com.au

About BLS Pharmaceuticals Limited

BLS Pharmaceuticals Limited (ASX:BLS) is an Australian pharmaceutical company focused on the manufacture, development and commercialisation of regulated therapeutic products and active pharmaceutical ingredients. Through its wholly owned subsidiary, Breathe Life Sciences, the Company operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products.

BLS has developed an international pharmaceutical manufacturing and distribution platform across Australia, Europe, the United Kingdom, Japan and Latin America. The Company specialises in final dose-form manufacturing, pharmaceutical distribution, contract manufacturing and international supply.

BLS sources pharmaceutical raw materials and active pharmaceutical ingredients from a global supplier network and manufactures products for both its own brands and third-party customers. The Company owns the Dr Watson® brand portfolio across multiple international markets and supplies pharmaceutical products, active pharmaceutical ingredients and manufacturing services to customers globally.

Corporate: **blspharma.com**

Australia: **bls.com.au**

International: **breathelifesciences.com**